BPC-157 is a peptide that has become increasingly popular in conversations about injury recovery, gut health, tissue repair and regenerative wellness.
It is especially well known among athletes and active adults exploring ways to support tendons, ligaments and muscles. BPC-157 has also attracted attention for its potential role in maintaining the gastrointestinal lining and supporting the body’s response to inflammation.
BPC-157 is available through some healthcare providers as a compounded injectable treatment or oral capsule. Here’s what we currently know about how it works, what researchers have studied and what to expect if you are considering treatment.
What Is BPC-157?
BPC-157 is a synthetic peptide made from a sequence of 15 amino acids. Its name comes from “Body Protection Compound,” a larger protective protein associated with human gastric juice.
The peptide was developed from a portion of that protein believed to contribute to the stomach’s natural ability to protect and repair its lining. BPC-157 is unusually stable in gastric environments, which has helped drive interest in both oral and injectable formulations.
Although its origins are connected to the gastrointestinal system, researchers have explored its activity in many other tissues, including:
- Tendons
- Ligaments
- Muscles
- Bone
- Skin
- Blood vessels
- Nerves
- The stomach and intestines
This broad range of research has made BPC-157 one of the most recognizable peptides in recovery-focused wellness.
The History of BPC-157
BPC-157 began appearing in published research during the 1990s. Early studies focused primarily on its possible protective effects within the gastrointestinal tract.
Researchers evaluated the peptide in animal models involving stomach ulcers, intestinal injuries and tissue damage associated with certain medications. The findings suggested that BPC-157 could influence the processes involved in protecting and restoring the gastrointestinal lining.
Interest later expanded beyond the gut. Studies began examining the peptide in models of tendon rupture, ligament injury, muscle damage, bone healing and nerve recovery.
Over time, BPC-157 became especially popular within sports medicine and performance communities because many of the tissues studied—particularly tendons and ligaments—can be slow to heal due to limited blood flow.
Today, BPC-157 is most commonly discussed in connection with:
- Muscle and joint recovery
- Tendon and ligament support
- Gastrointestinal health
- Tissue repair
- Blood-flow support
- Inflammatory balance
- Recovery from physical activity
- Overall regenerative wellness
How Does BPC-157 Work?
BPC-157 appears to influence several connected parts of the repair process rather than acting through one isolated pathway.
Blood-Vessel Formation and Circulation
Injured tissue needs blood flow to receive oxygen, nutrients and the cells involved in repair.
Experimental research suggests that BPC-157 may support angiogenesis, the process through which new blood vessels form. It has been studied for its relationship with vascular endothelial growth factor, commonly called VEGF, and other signals involved in rebuilding circulation around damaged tissue.
This proposed effect is one reason researchers have been interested in BPC-157 for tendons, ligaments and other areas where circulation can be limited.
Tendon and Connective-Tissue Activity
Tendons and ligaments are made largely from collagen and other connective-tissue proteins. Their recovery depends on the movement, growth and organization of specialized repair cells.
Laboratory research has found that BPC-157 may support tendon fibroblast survival and migration. Fibroblasts are cells that help produce collagen and rebuild the structural framework of connective tissue.
Researchers have also explored BPC-157’s interaction with growth-factor pathways involved in tissue repair. These findings have contributed to its popularity among people focused on mobility, physical performance and recovery.
Gastrointestinal-Lining Support
BPC-157’s relationship with the digestive system remains a major part of its research history.
The lining of the stomach and intestines acts as a barrier between the contents of the digestive tract and the rest of the body. That barrier must continually maintain and repair itself.
Animal and laboratory studies suggest that BPC-157 may support the movement and growth of cells involved in restoring gastrointestinal tissue. It has been studied in models involving ulcers, intestinal damage, inflammatory conditions and injuries to different sections of the digestive tract.
This gut-focused research is also why BPC-157 is available in oral capsule form through some peptide-therapy providers.
Inflammatory and Nitric-Oxide Pathways
BPC-157 has been associated with changes in inflammatory signals involved in the body’s response to injury.
Researchers have also studied its relationship with nitric oxide, a signaling molecule that helps regulate blood-vessel function and circulation. BPC-157 appears to interact with this system in a context-dependent way, potentially helping support normal vascular activity during tissue repair.
These pathways may connect many of the peptide’s proposed effects involving circulation, inflammation and cellular recovery.
What Does the Research Say About BPC-157?
BPC-157 has been studied in laboratory experiments, animal models and a small number of human reports. Most of the current evidence comes from preclinical research.
Laboratory Research
Laboratory studies help researchers observe how BPC-157 affects individual cells and repair-related pathways.
These experiments have associated the peptide with:
- Tendon-fibroblast movement and survival
- Growth-factor signaling
- Blood-vessel formation
- Collagen and connective-tissue activity
- Cellular protection under stress
- Inflammatory signaling
- Nitric-oxide regulation
One frequently cited study found that BPC-157 promoted the outgrowth, survival and migration of tendon fibroblasts under laboratory conditions. Other research has explored how the peptide interacts with VEGF, growth hormone receptors and signaling pathways involved in cellular movement.
These findings help explain why BPC-157 is being investigated across several different types of tissue.
Animal Research
Animal research represents the largest portion of the BPC-157 evidence.
Studies have examined the peptide in models involving:
- Achilles tendon injuries
- Ligament damage
- Muscle tears
- Bone fractures
- Gastrointestinal ulcers
- Intestinal injuries
- Skin wounds
- Nerve damage
A 2025 systematic review evaluated 36 BPC-157 studies published between 1993 and 2024. Of those, 35 were preclinical studies. Across animal models, researchers reported improvements in various structural, functional and biomechanical measures involving muscle, tendon, ligament and bone injuries.
For example, rat studies involving Achilles tendon injuries reported improvements in tendon healing and function. Other models have produced encouraging findings involving ligament strength, muscle recovery and bone repair.
This research provides much of the scientific foundation behind BPC-157’s reputation as a recovery peptide.
Human Research
Published human research involving BPC-157 remains relatively small but is beginning to grow.
A retrospective study evaluated 12 patients who received an intra-articular BPC-157 injection for chronic knee pain. Eleven reported meaningful improvement, and seven reported relief lasting longer than six months.
Because the study was small and did not include a placebo comparison, larger controlled trials will be needed to determine how consistently those results can be reproduced.
A 2025 pilot study also evaluated intravenous BPC-157 in two adults. Both participants received 10-milligram and 20-milligram infusions. Researchers reported no side effects or measurable negative changes in the heart, liver, kidney, thyroid or blood-glucose markers evaluated during the study period.
These early findings provide a starting point for additional human research. Larger studies will help clarify which applications are most promising, how different forms of BPC-157 compare and what treatment protocols produce the most consistent results.
Is BPC-157 FDA-Approved?
As of August 2026, BPC-157 is not an FDA-approved medication, but it recently received an encouraging regulatory recommendation.
On July 23, 2026, the FDA’s Pharmacy Compounding Advisory Committee voted 8–6, with one abstention, to recommend adding both BPC-157 free base and BPC-157 acetate to the 503A Bulks List. If the FDA adopts the recommendation, licensed compounding pharmacies would have a clearer pathway to prepare BPC-157 medications for patients with prescriptions.
The committee’s vote does not grant formal FDA approval and remains subject to a final FDA decision. Still, it represents meaningful progress for BPC-157 and reflects growing recognition of the interest in expanding access through appropriately regulated compounding pharmacies.
More information is available through the FDA’s July 2026 advisory committee materials.
What Does Compounded BPC-157 Mean?
A compounded medication is prepared by a licensed pharmacy or qualified compounding facility based on a healthcare provider’s prescription.
Compounded treatments may be prepared in particular strengths or dosage forms to support an individual treatment plan. BPC-157 may be prescribed in forms such as subcutaneous injections or oral capsules, depending on the provider, pharmacy and patient’s goals.
Why Are Clinicians and Researchers Interested in BPC-157?
BPC-157 has attracted attention because it appears to connect several important parts of the recovery process: circulation, cellular movement, connective-tissue activity, inflammatory signaling and gastrointestinal protection.
Interest continues because BPC-157:
- Is based on a peptide sequence associated with the stomach’s protective system
- Remains stable in gastric environments
- Has been studied for more than three decades
- Has produced encouraging findings across multiple animal injury models
- May influence blood-vessel and growth-factor signaling
- Has applications involving both gastrointestinal and musculoskeletal wellness
- Is now beginning to receive more direct human research
For active adults, the appeal is fairly straightforward: BPC-157 is being studied in many of the tissues that frequently limit mobility, training and recovery.
For clinicians and researchers, the peptide presents an opportunity to explore how several repair-related pathways may be supported through one treatment. Continued human research will help define where BPC-157 fits most effectively within regenerative medicine and individualized wellness plans.
BPC-157 Therapy at RegenMD Wellness
RegenMD Wellness offers compounded BPC-157 therapy to eligible patients following consultation with a licensed healthcare provider.
BPC-157 is available through RegenMD as a standalone injectable peptide and in oral capsule form. It is also included in certain combination therapies, such as Recovery Blend and Sleep Blend, and may be paired with TB-500 in oral capsules for patients with overlapping gastrointestinal and musculoskeletal recovery goals.
During the consultation process, a provider reviews factors such as:
- Medical history
- Current medications and supplements
- Wellness and recovery goals
- Previous injuries and treatments
- Gastrointestinal concerns
- Allergies and potential risk factors
- Preferred method of administration
- Appropriate treatment monitoring
If BPC-157 is considered appropriate, the provider determines the formulation, dose, schedule, treatment length and follow-up plan for that patient.
Eligibility is established through the clinical evaluation, and completing a consultation does not guarantee that BPC-157 will be prescribed. Patients who begin treatment should follow their provider’s instructions and communicate any side effects, health changes or questions during the treatment process.
This article is provided for general educational purposes and does not constitute medical advice. Research discussed may include laboratory, animal, and human studies. Patients should always consult a licensed clinician when considering peptide therapy.
Sources
- Vasireddi N, et al. “Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review.” HSS Journal. 2025.
- McGuire FP, et al. “Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing.” 2025.
- Gwyer D, et al. “Gastric Pentadecapeptide Body Protection Compound BPC 157 and Its Role in Accelerating Musculoskeletal Soft Tissue Healing.” Cell and Tissue Research. 2019.
- Chang CH, et al. “The Promoting Effect of Pentadecapeptide BPC 157 on Tendon Healing Involves Tendon Outgrowth, Cell Survival and Cell Migration.” Journal of Applied Physiology. 2011.
- Cerovecki T, et al. “Pentadecapeptide BPC 157 Improves Ligament Healing in the Rat.” Journal of Orthopaedic Research. 2010.
- Staresinic M, et al. “Gastric Pentadecapeptide BPC 157 Accelerates Healing of Transected Rat Achilles Tendon.” Journal of Orthopaedic Research. 2003.
- Lee E, Padgett B. “Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain.” Alternative Therapies in Health and Medicine. 2021.
- Lee E, et al. “Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study.” 2025.
- U.S. Food and Drug Administration. “Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks.”
- U.S. Food and Drug Administration. “Pharmacy Compounding Advisory Committee Briefing Document for BPC-157-Related Bulk Drug Substances.” July 2026.
- U.S. Food and Drug Administration. “Compounding and the FDA: Questions and Answers.”
- U.S. Food and Drug Administration. “July 23–24, 2026 Meeting of the Pharmacy Compounding Advisory Committee.” July 2026.
